Ad
related to: switching from colchicine to allopurinol for cancer prevention drug
Search results
Results From The WOW.Com Content Network
While colchicine is not used to treat cancer in humans, it is commonly used to treat acute attacks of gout. [26] Colchicine is an anti-inflammatory drug that has been in continuous use for more than 3000 years. Colchicine is an oral drug, known to be used for treating acute gout and preventing acute attacks of familial Mediterranean fever (FMF).
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
ATC code M04 Antigout preparations is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup M04 is part of the anatomical group M Musculo-skeletal system. [4]
Allopurinol is a medication used to decrease high blood uric acid levels. [5] It is specifically used to prevent gout, prevent specific types of kidney stones and for the high uric acid levels that can occur with chemotherapy. [6] [7] It is taken orally (by mouth) or intravenously (injected into a vein). [7]
Generally, drugs outlined within the ATC code M04 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antigout agents .
A xanthine oxidase inhibitor is any substance that inhibits the activity of xanthine oxidase, an enzyme involved in purine metabolism.In humans, inhibition of xanthine oxidase reduces the production of uric acid, and several medications that inhibit xanthine oxidase are indicated for treatment of hyperuricemia and related medical conditions including gout. [1]
Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase [1] used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects. It is structurally related to the antiarrhythmic amiodarone. [2]
In July 2009, the FDA approved colchicine as a monotherapy for the treatment of three different indications (familial Mediterranean fever, acute gout flares, and for the prophylaxis of gout flares [66]). This resulted in a 3-year regulatory market exclusivity in the acute and chronic gout indications and a 7-year exclusivity on the FMF indication.